Dr. Sehbanul Islam received his master’s degree in biotechnology from Aligarh Muslim University, India, and completed his Ph.D. at the National Centre for Cell Science (NCCS), Pune, India. He is currently a Senior Postdoctoral Researcher in the Department of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania. Dr. Islam’s expertise lies in the ubiquitin–proteasome system and its role in cancer progression and DNA damage response pathways. His research focuses on targeting oncogenic proteins through small-molecule–induced targeted protein degradation, to advance precision oncology by developing strategies that selectively eliminate disease-driving proteins. In his recent work, Dr. Islam demonstrated that the combinatorial use of two PROTACs can synergistically enhance degradation efficiency and overcome the hook effect, a known limitation in PROTAC-based therapies. In addition, he developed TAP-DBP (Tandem Affinity Purification for Drug-Binding Protein identification), a robust and scalable method for identifying the cellular protein targets of small molecules. His research continues to advance the mechanistic understanding and therapeutic potential of ubiquitin–proteasome system and targeted protein degradation in cancer biology.